<DOC>
	<DOCNO>NCT02039492</DOCNO>
	<brief_summary>Background : In hypertension , highly prevalent disease , 10-15 % hypertensive patient uncontrolled blood pressure despite regimen ≥ 3 drug , know resistant hypertension ( RH ) . Cardiovascular prognosis patient RH bad control hypertensive . Efferent renal sympathetic nerve play important role volume homeostasis blood pressure . A novel minimally invasive technique base use selective radiofrequency renal sympathetic denervation show promising preliminary result treatment patient . On hand , patient RH could improve blood pressure control add spironolactone , antagonist aldosterone receptor . Objective : To evaluate efficacy radiofrequency renal sympathetic denervation patient RH , compare addition spironolactone therapeutic regimen baseline . Method : interventional , prospective , randomize , open study , cohort 50 patient RH , office systolic blood pressure ≥ 150 mmHg also 24h systolic blood pressure ≥ 140 mmHg , despite treatment ≥ 3 drug adequate dos , one diuretic , whitout treatment either spironolactone eplerenone . Patients randomize ( 1:1 ) renal sympathetic denervation treatment spironolactone ( 50mg ) , perform determination office blood pressure 24h-ABPM pre-randomization , 1 , 3 6 month , well laboratory test , echocardiography , measurement carotid intima-media thickness central blood pressure measurement pre-randomization 6 month .</brief_summary>
	<brief_title>Sympathetic Renal Denervation Versus Increment Pharmacological Treatment Resistant Arterial Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Subjects age ≥ 18 year ≤ 80 year . 2 . Subjects diagnose resistant arterial hypertension ( office blood pressure ≥ 140 and/or 90 mm Hg despite treatment least 3 antihypertensive drug give maximum tolerated therapeutic dosage , one diuretic ) , therapeutic regimen maintain least last 3 month . 3 . Office systolic blood pressure ≥150 mm Hg , confirmation resistance treatment 24h ambulatory blood pressure monitoring , 24hsystolic blood pressure ≥140 mmHg require include . 4 . Patients freely give informed consent writing , nature study disclosure data explain . 1 . Secondary hypertension , renovascular disease include appropriate test accord investigator criterion ( exception chronic renal disease obstructive sleepapnea syndrome ) . 2 . Inability perform magnetic resonance angiography renal CT angiography ( contrast allergy ) . 3 . Patients unlikely compliant treatment ( assess accord HaynesSackett test ) . 4 . Patients currently treatment aldosterone receptor blocker ( spironolactone , eplerenone ) previously receive one class drug withdraw due lack efficacy and/or adverse effect . 5 . Stage 3B , 4 5 chronic renal disease ( estimate glomerular filtration rate MDRD equation &lt; 45 mL/min/1.73m2 ) . 6 . Prerandomization serum potassium ( K+ ) level ≥ 5.5 mmol/L . 7 . Significant renal vascular anomaly . 8 . Pregnant woman . 9 . Significant valvular heart disease . 10 . Major vascular event ( myocardial infarction , unstable angina cerebrovascular disease ) &lt; 6 month prior study enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>